News

Idenix Pharma’s net loss was $13.91m, or $0.15 loss per diluted share, compared to net loss of $16.26m, or $0.23 loss per diluted share, for the same period

Unigene’s net loss was $8.44m, or $0.09 loss per diluted share, compared to net loss of $3.64m, or $0.04 loss per diluted share, for the same period in

As per the terms of the agreement, GSK will pay $2.2m as milestones to Unigene for the development and manufacturing activities. These activities are connected to the active

Under the agreement, the companies will develop Genentech’s compound GDC-0425 (RG7602) and Array’s ARRY-575. The tie up allows Genentech to take care of all clinical development and commercialization

Pfizer expects to invest up to $50m for research programs and milestone payments to UC San Diego Health Sciences for successful projects. The tie up allows the scientists

The agreement allows Acurian to use encryption and security standards to manage sensitive patient data handled within its Oracle- and cloud-based computing platforms known as Acurian Recruitment Manager

Levetiracetam Injection is indicated as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Innopharma’s levetiracetam injection is the generic version of UCB’s Keppra

The NDA is supported by the results of two Phase III clinical trials evaluating the efficacy and safety of BDP Nasal HFA which showed improvement in nasal symptoms

The new patent named, ‘Neurotherapeutic compositions comprising a beta-lactam compound,’ includes compounds including clavulanic acid and moxalactam as a treatment for neurological disorders like, Alzheimer’s disease, anxiety, dementia,